Brady Collins
Rotavirus is a common infection that causes fever, vomiting, and diarrhea, and can lead to severe dehydration, hospitalization, and even death in some cases. Fortunately, there are vaccines available to protect against rotavirus infection, which is great news as nearly all children are infected with rotavirus by the age of five. Two types of rotavirus vaccines are available for infants in the United States: RotaTeq and Rotarix. Both are oral vaccines, given in the form of drops, and are safe and effective at preventing severe disease. The World Health Organization recommends including rotavirus vaccines in national immunization schedules, and many countries have introduced routine vaccination, resulting in significant decreases in deaths and hospitalizations.
| Characteristics | Values |
|---|---|
| Number of available vaccines | 2 |
| Names of vaccines | RotaTeq, Rotarix |
| Type of vaccines | RotaTeq: Live, oral, pentavalent vaccine; Rotarix: Monovalent, human, live attenuated vaccine |
| Number of doses | RotaTeq: 3 doses; Rotarix: 2 doses |
| Age of administration | First dose: 6-12 weeks; Second dose: 10-14 weeks; Third dose: 18-26 weeks |
| Effectiveness | 9 out of 10 vaccinated will be protected from severe rotavirus disease; 7 out of 10 will be protected from rotavirus disease of any severity |
| Side effects | Mild and temporary: Irritability, diarrhea, vomiting; Rare: Intussusception (bowel blockage) |
| Availability | Licensed in more than 100 countries; Routinely used in over 80 countries |
| Cost | US$5 per dose in low- and middle-income countries |
| Storage | N/A |
| Administration | Oral drops |
Explore related products
What You'll Learn
Rotavirus vaccines are safe and effective
Two types of rotavirus vaccines are available for infants in the United States, and both are safe and effective. These vaccines are RotaTeq (RV5) and Rotarix (RV1), which have been approved for use since 2006 and 2008, respectively. RotaTeq is given in three doses at 2, 4, and 6 months of age, while Rotarix is given in two doses at 2 and 4 months of age. Both vaccines are oral and are administered by putting drops into the infant's mouth.
Clinical trials involving thousands of infants have shown that the vaccines are safe and effective. About 9 out of 10 vaccinated infants will be protected from severe rotavirus disease, and 7 out of 10 will be protected from rotavirus disease of any severity. Vaccinated children are less likely to get sick from rotavirus, and the vaccines have been shown to reduce hospitalizations and deaths from rotavirus diarrhea. In the United States, for example, rotavirus-related hospitalizations have decreased by up to 86% since 2006.
While some babies may experience mild side effects such as irritability, mild diarrhea, or vomiting after vaccination, these usually go away on their own. Serious side effects are rare, but there is a small risk of intussusception (a rare type of bowel blockage) within a week after the first or second dose of the vaccine. However, the benefits of the rotavirus vaccine clearly outweigh the risks, and it is recommended that infants receive two or more doses of the vaccine to protect against rotavirus disease.
Influenza Vaccination Policy: What's the Truth?
You may want to see also
Explore related products
Vaccines are given orally
There are currently two types of rotavirus vaccines available for infants in the United States: RotaTeq (RV5) and Rotarix (RV1). Both vaccines are given orally, in the form of drops placed in the infant's mouth. RotaTeq is given in three doses at 2, 4, and 6 months of age, while Rotarix is administered in two doses at 2 and 4 months of age. The first dose of either vaccine should be given before the child reaches 15 weeks of age, and all doses should be completed by the time the child turns 8 months old.
The oral administration of these vaccines is a safe and effective method of protecting infants against rotavirus disease. Rotavirus infections are common in children and can cause severe symptoms such as fever, vomiting, and diarrhea, leading to dehydration, hospitalization, and, in some cases, even death. The vaccines have been proven to significantly reduce the incidence and severity of rotavirus infections, with about 9 out of 10 vaccinated individuals being protected from severe disease.
RotaTeq, the first rotavirus vaccine, was developed using a combination of a calf rotavirus strain and human rotavirus proteins. This unique combination allows babies to develop immunity without experiencing the disease itself. The second vaccine, Rotarix, is created from a single type of rotavirus that has been weakened in a laboratory setting. Extensive studies have shown that Rotarix does not cause vomiting, diarrhea, fever, irritability, or poor feeding.
Both RotaTeq and Rotarix are licensed in more than 100 countries, and their introduction has led to a substantial reduction in rotavirus-related hospitalizations and deaths, especially in developing nations. The World Health Organization strongly recommends including these vaccines in national immunization schedules, emphasizing the low risk of intussusception compared to the significant benefits of preventing deadly diarrhoea.
Pregnant Women and Flu Shots: What's Safe?
You may want to see also
Explore related products
Two types of vaccines are available
Rotavirus is a common infection that spreads easily and can cause fever, vomiting, and watery diarrhea. It can lead to a loss of body fluids (dehydration), hospitalization, and even death in some cases, especially in children. The World Health Organization (WHO) recommends that the rotavirus vaccine be included in all national immunization schedules.
Two types of rotavirus vaccines are available for infants in the United States, and both are safe and effective. The first vaccine, RotaTeq (RV5), was approved for use in 2006 and is given in three doses at 2, 4, and 6 months of age. The second vaccine, Rotarix (RV1), was approved in 2008 and is administered in two doses at 2 and 4 months of age. Both vaccines are oral and are given by putting drops into the infant's mouth. They can also be safely administered during the same doctor's visit as other routine vaccines such as the DTaP, Hib, polio, hepatitis B, and pneumococcal conjugate vaccines.
RotaTeq is a live, oral, pentavalent vaccine that contains five rotavirus strains produced by reassortment. It is made from a combination of a calf rotavirus, which cannot cause disease in children, and human rotavirus proteins that protect against the disease. This combination allows babies to develop immunity without getting sick. RotaTeq was extensively tested and approved by the Food and Drug Administration (FDA) in 2006.
On the other hand, Rotarix is a monovalent, human, live attenuated rotavirus vaccine containing one rotavirus strain of G1P [8] specificity. It is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when given as a 2-dose series. Rotarix was approved in the European Union in 2006 and by the US FDA in 2008. It is important to note that Rotarix is made from one type of rotavirus that was originally isolated from a person and then weakened in the lab. Studies have shown that this vaccine does not cause vomiting, diarrhea, fever, irritability, or poor feeding.
Both vaccines have been found to be safe and effective in preventing severe rotavirus disease. About 9 out of 10 vaccinated individuals will be protected from severe rotavirus disease, and 7 out of 10 will be protected from rotavirus disease of any severity. Vaccinated children are less likely to experience severe symptoms, and the vaccines have reduced rotavirus-related hospitalizations and deaths, especially in developing countries.
Spouse Vaccination: Essential Workers' Eligibility
You may want to see also
Explore related products
$24.17 $25.99
Vaccines are recommended for infants
Rotavirus is a common infection that spreads easily. It infects the lining of the intestines and causes fever, vomiting, and watery diarrhea. In some cases, rotavirus can lead to severe dehydration, hospitalization, and even death. Before the vaccine was available, nearly all children were infected with rotavirus by the age of five, with illness usually occurring between the ages of three months and two years.
Two types of rotavirus vaccines are available for infants in the United States: RotaTeq and Rotarix. Both vaccines are given by mouth in the form of drops and are safe and effective. RotaTeq is given in three doses at 2, 4, and 6 months of age, while Rotarix is given in two doses at 2 and 4 months of age. Both vaccines should be administered before the child reaches 8 months old.
While the rotavirus vaccine is recommended for most infants, there are some exceptions. Infants with severe allergies, severe combined immunodeficiency (SCID), or a previous episode of intussusception should not receive the vaccine or should wait until these conditions resolve. Infants who are moderately or severely ill should also wait until they recover before getting the vaccine. It is important to consult with a healthcare provider to determine if the rotavirus vaccine is suitable for your child.
Antibodies vs. Vaccines: Which Offers Better Protection?
You may want to see also
Explore related products
Vaccines have reduced hospitalisations
Rotavirus is a common infection that spreads easily and can cause severe symptoms in children, such as fever, vomiting, and diarrhea, which can lead to life-threatening dehydration. Before the introduction of vaccines, nearly all children were infected with rotavirus by the age of five, and many required hospitalization.
The development and widespread adoption of rotavirus vaccines have significantly reduced hospitalization rates. Two types of vaccines, RotaTeq and Rotarix, are currently licensed for use in infants in the United States and are given orally in two or three doses, respectively. These vaccines are safe and effective, with mild and rare side effects. Clinical trials have shown that about 9 out of 10 vaccinated children will be protected from severe rotavirus disease, and 94% to 96% will avoid hospitalization.
The impact of rotavirus vaccines is evident in various countries. In the United States, rotavirus-related hospitalizations have decreased by up to 86% since 2006. In Mexico, the introduction of the vaccine in 2006 led to a more than 65% drop in diarrheal disease death rates among children under two during the 2009 rotavirus season. Nicaragua, the first developing country to introduce the vaccine in 2006, saw a substantial impact, with a 60% reduction in severe rotavirus cases and a halving of emergency room visits.
The World Health Organization recommends including rotavirus vaccines in national immunization schedules due to their proven effectiveness in preventing severe and deadly diarrhea. This recommendation has been implemented in over 80 countries, with more than 100 countries licensing the vaccines. The vaccines have been particularly beneficial in developing countries, where the majority of rotavirus-related deaths occur, as they have dramatically reduced severe disease and death rates.
Overall, the availability and administration of rotavirus vaccines have substantially reduced hospitalization rates, protecting children from severe illness and potentially life-threatening complications.
Vaccines: Stopping the Spread of Infection
You may want to see also
Frequently asked questions
Yes, there are two types of rotavirus vaccines available for infants in the United States: RotaTeq and Rotarix. Both are safe and effective and are given by mouth in the form of drops.
About 9 out of 10 infants who get the vaccine will be protected from severe rotavirus disease. About 7 out of 10 children will be protected from rotavirus disease of any severity. Vaccination has reduced rotavirus-related hospitalizations by up to 86% in the United States.
Most babies who get the rotavirus vaccine have no problems. However, mild and temporary side effects may include irritability, diarrhea, and vomiting. Serious side effects are rare but may include intussusception, a rare type of bowel blockage.
Two or more doses of the rotavirus vaccine are recommended for children. RotaTeq is given in three doses at 2, 4, and 6 months of age, while Rotarix is given in two doses at 2 and 4 months of age.
